Rapid Micro Biosystems to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

Rhea-AI Summary

Rapid Micro Biosystems (Nasdaq: RPID) announced participation in the Morgan Stanley 19th Annual Global Healthcare Conference on September 15, 2021. CEO Rob Spignesi and CFO Sean Wirtjes will engage in a 30-minute virtual Q&A session starting at 5:00 AM PT (8:00 AM ET). Investors can access the live webcast on the company’s website, which will be archived for 90 days post-event. The company specializes in automation solutions for healthcare products, enhancing microbial quality control testing in pharmaceutical manufacturing.

LOWELL, Mass., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that it will be participating in the Morgan Stanley 19th Annual Global Healthcare Conference on Wednesday, September 15^th, 2021.

Rob Spignesi, President and CEO, and Sean Wirtjes, CFO, are scheduled to participate in a virtual 30-minute question-and-answer session with the host analyst beginning at 5:00am Pacific Time/8:00am Eastern Time. A live webcast of the session will be available on the Company's website at https://investors.rapidmicrobio.com/. The webcast will then be archived and available for replay for 90 days after the event.

About Rapid Micro Biosystems

Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company’s flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct platform brings the quality control lab to the manufacturing floor, unlocking the power of in-line/at-the-line MQC automation to deliver faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making, that customers rely on to ensure safe and consistent supply of important healthcare products. The company is headquartered and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the company on Twitter at @rapidmicrobio or on LinkedIn.

FAQ

What is the date of Rapid Micro Biosystems' participation in the Morgan Stanley Global Healthcare Conference?

Rapid Micro Biosystems will participate in the conference on September 15, 2021.

Who will represent Rapid Micro Biosystems at the Morgan Stanley Global Healthcare Conference?

Rob Spignesi, President and CEO, and Sean Wirtjes, CFO, will represent the company.

What time will the Q&A session take place for Rapid Micro Biosystems at the conference?

The Q&A session will begin at 5:00 AM Pacific Time (8:00 AM Eastern Time).

How can investors access the Rapid Micro Biosystems conference webcast?

Investors can access the webcast live on the company's website, where it will be archived for 90 days.

What technology does Rapid Micro Biosystems offer for healthcare product manufacturing?

The company provides automation solutions through its Growth Direct platform, which modernizes microbial quality control testing.